ELVN
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) has 4 SEC Form 4 filings (11 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 8, 2026.
Insiders have net sold $52.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Richard A. Fair
- Employees:62
- HQ:Boulder, CO, US
- IPO:2020-03-12
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$52.5M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$3.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 10,000 | $505K | Jul 8 | SEC ↗ | |
| 10% Owner | Sale | 860,123 | $39.0M | Jun 24 | SEC ↗ | |
| 10% Owner | Sale | 281,408 | $12.7M | Jun 17 | SEC ↗ | |
Kunkel Lori AnneFirst filing | Director | Sale | 10,000 | $345K | Jun 9 | SEC ↗ |
Related companies
Enliven Therapeutics, Inc. is in the Healthcare sector.